Wonder Why Gilead Sciences Bought Kite Pharma? Here’s the Answer!
The next big thing in cancer treatment could be chimeric-antigen receptor T-cell therapy, or CAR-T, a novel approach that uncloaks cancer cells so that the immune system can destroy them. The promise of CAR-T is so big that biotech behemoth Gilead Sciences (NASDAQ: GILD) is paying $11.9 billion to acquire Kite Pharma (NASDAQ: KITE), a company that's at the forefront of CAR-T development.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass is joined by Todd Campbell to explain CAR-T and why it could move the needle for Gilead Sciences investors.
A full transcript follows the video.
Source: Fool.com